Advisory Resource Group Has $4.85 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Advisory Resource Group lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 16.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,502 shares of the company’s stock after buying an additional 4,633 shares during the period. Advisory Resource Group’s holdings in Johnson & Johnson were worth $4,845,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Powers Advisory Group LLC grew its stake in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after buying an additional 61 shares during the period. Knuff & Co LLC grew its stake in Johnson & Johnson by 0.7% in the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock valued at $1,534,000 after acquiring an additional 64 shares during the period. Vertex Planning Partners LLC increased its holdings in shares of Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after acquiring an additional 65 shares in the last quarter. Freedom Day Solutions LLC raised its position in shares of Johnson & Johnson by 1.1% during the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock worth $1,016,000 after purchasing an additional 66 shares during the period. Finally, Traphagen Investment Advisors LLC grew its position in Johnson & Johnson by 0.6% in the 3rd quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company’s stock valued at $1,699,000 after purchasing an additional 67 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $156.18 on Wednesday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The firm’s 50-day simple moving average is $147.40 and its two-hundred day simple moving average is $156.04. The firm has a market cap of $376.02 billion, a price-to-earnings ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the business earned $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Stifel Nicolaus dropped their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Finally, Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.